Understand the source comparison
Peptides for GERD Natural Treatment Protocol Evidence Guide: Dosing Comparison
BPC-157 250–500 mcg daily Upregulates VEGF-A and eNOS; promotes angiogenesis and epithelial repair 30–60 minutes before meals on empty stomach Moderate (multiple animal studies, no human RCTs) Most mechanistically robust for mucosal healing; timing critical to
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- 250–500 mcg daily
- Upregulates VEGF-A and eNOS; promotes angiogenesis and epithelial repair
- 30–60 minutes before meals on empty stomach
- Moderate (multiple animal studies, no human RCTs)
- Most mechanistically robust for mucosal healing; timing critical to avoid gastric degradation
- KPV (5mg)
- 500–1000 mcg daily
- Inhibits NF-kappa-B; reduces IL-6, IL-1-beta, TNF-alpha inflammatory cascade
- Independent of meal timing (systemic effect)
- Low-Moderate (colitis models, no esophagitis-specific trials)
- Strong anti-inflammatory profile; less direct evidence for epithelial repair than BPC-157
- Thymosin Beta-4
- 2–5 mg twice weekly
- Actin sequestration; promotes epithelial progenitor cell migration and differentiation
- Independent of meal timing
- Low (ulcer models, wound healing trials in non-GI tissue)
- Promising for barrier restoration; dosing extrapolated from non-GI wound studies
- Combination Protocol (BPC-157 + KPV)
- 250 mcg BPC-157 + 500 mcg KPV daily
- Dual action: mucosal repair + inflammation suppression
- BPC-157 fasted; KPV flexible
- Theoretical (no published combination trials)
- Rationale is mechanistically sound; no safety or efficacy data in combination